COVID-19 Time of Intubation Mortality Evaluation (C-TIME): A system for predicting mortality of patients with COVID-19 pneumonia at the time they require mechanical ventilation

Robert A. Raschke\(^1,2\)*, Pooja Rangan\(^2,3\), Sumit Agarwal\(^2,3\), Suresh Uppalapu\(^2,3\), Nehan Sher\(^2\), Steven C. Curry\(^1,4\), C. William Heise\(^1,4\)

\(^1\) The Division of Clinical Data Analytics and Decision Support, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States of America, \(^2\) University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States of America, \(^3\) Department of Internal Medicine, Banner—University Medical Center Phoenix, Phoenix, AZ, United States of America, \(^4\) Department of Medical Toxicology, Banner—University Medical Center Phoenix, Phoenix, AZ, United States of America

* Raschkebob@gmail.com

Abstract

Background

An accurate system to predict mortality in patients requiring intubation for COVID-19 could help to inform consent, frame family expectations and assist end-of-life decisions.

Research objective

To develop and validate a mortality prediction system called C-TIME (COVID-19 Time of Intubation Mortality Evaluation) using variables available before intubation, determine its discriminant accuracy, and compare it to acute physiology and chronic health evaluation (APACHE IVa) and sequential organ failure assessment (SOFA).

Methods

A retrospective cohort was set in 18 medical-surgical ICUs, enrolling consecutive adults, positive by SARS-CoV 2 RNA by reverse transcriptase polymerase chain reaction or positive rapid antigen test, and undergoing endotracheal intubation. All were followed until hospital discharge or death. The combined outcome was hospital mortality or terminal extubation with hospice discharge. Twenty-five clinical and laboratory variables available 48 hours prior to intubation were entered into multiple logistic regression (MLR) and the resulting model was used to predict mortality of validation cohort patients. Area under the receiver operating curve (AUROC) was calculated for C-TIME, APACHE IVa and SOFA.
Results

The median age of the 2,440 study patients was 66 years; 61.6 percent were men, and 50.5 percent were Hispanic, Native American or African American. Age, gender, COPD, minimum mean arterial pressure, Glasgow Coma scale score, and PaO$_2$/FiO$_2$ ratio, maximum creatinine and bilirubin, receiving factor Xa inhibitors, days receiving non-invasive respiratory support and days receiving corticosteroids prior to intubation were significantly associated with the outcome variable. The validation cohort comprised 1,179 patients. C-TIME had the highest AUROC of 0.75 (95%CI 0.72–0.79), vs 0.67 (0.64–0.71) and 0.59 (0.55–0.62) for APACHE and SOFA, respectively (Chi$^2$ P<0.0001).

Conclusions

C-TIME is the only mortality prediction score specifically developed and validated for COVID-19 patients who require mechanical ventilation. It has acceptable discriminant accuracy and goodness-of-fit to assist decision-making just prior to intubation. The C-TIME mortality prediction calculator can be freely accessed on-line at https://phoenixmed.arizona.edu/ctime.

Introduction

The Coronavirus disease 2019 (COVID-19) pandemic raised concern that an overwhelming surge of critically-ill patients might require exclusion of patients with high predicted mortality from receiving mechanical ventilation [1]. The majority of COVID-19 ventilator triage policies surveyed in 2020 incorporated the Sequential Organ Failure Assessment (SOFA) score to predict mortality [2]. The SOFA score was originally designed to predict the mortality of sepsis patients based on assessment of the respiratory, renal, cardiovascular, hepatobiliary, coagulation and central nervous systems [3], and was externally validated in general ICU patient populations [4, 5]. However, a recent study using SOFA score data collected 48 hours prior to intubation in patients with COVID-19 pneumonia yielded a discriminant accuracy for mortality prediction of only 0.59 (95%CI: 0.55–0.63) [6]. Among other general ICU mortality scoring systems, the acute physiology and chronic health evaluation, version IVa (APACHE IVa) is notable, incorporating 145 variables and disease-specific regression models [7]. APACHE IVa has been shown to have superior discriminant accuracy compared to other general ICU mortality prediction models [8–10] and has been externally validated for COVID-19 patients [11], but it is based on variables obtained at the time of admission rather than at the time of intubation. Although many other scoring systems have been specifically developed to predict mortality in patients with COVID-19 [12–34], none focused on assessing the patient at the time of intubation, when patients, families and providers are forced to make critical decisions regarding life support. Informed consent for endotracheal intubation should include an objective discussion of prognosis, and the need for ventilator triage based on predicted mortality might yet arise in future regional covid hotspots. Therefore, the point in time when it becomes apparent that a patient with COVID-19 pneumonia is going to require mechanical intubation is arguably the most important time to determine their prognosis. Our aim was to develop a mortality prediction system we called C-TIME (COVID-19 Time of Intubation Mortality Evaluation) using variables typically available in the 48 hours before intubation, in order to inform consent, frame family expectations and assist end-of-life planning. Our secondary aims were to
validate C-TIME, determine its discriminant accuracy and calibration, and compare it to SOFA and APACHE IVa mortality prediction models.

**Materials and methods**

**Study design**

A retrospective cohort study, approved by the research determination committee of the University of Arizona IRB, with waived necessity for consent to use de-identified data, was set in 18 medical surgical ICUs in the Southwest United States between 6/1/2020 and 3/23/2021. June was chosen for cohort inception when preliminary results of the RECOVERY trial [35] were released, and administration of dexamethasone rapidly adopted in our study ICUs. We randomly assigned study patients to model-development and validation cohorts.

**Participants**

Consecutive ICU patients were included based on the following eligibility criteria: ≥18 years of age; positive SARS-CoV 2 RNA by reverse transcriptase polymerase chain reaction or positive rapid antigen test; and undergoing endotracheal intubation ≥4 hours after admission. All patients were followed until hospital discharge or death.

**Variables and data sources**

The main outcome variable was hospital mortality or discharge to hospice after terminal extubation—henceforth this combined outcome is referred to as “mortality”. We chose candidate predictor variables to use in model development based on previous literature [12–34] and hypotheses generated by our clinical research team. We examined our clinical dataset and only included candidate predictor variables that were missing in less than 10% of study patients. We made an exception for the partial pressure of arterial oxygen/fraction of inspired oxygen (PaO$_2$/FiO$_2$) ratio, which we hypothesized would be a particularly important predictor [36]; therefore we planned a-priori to impute missing PaO$_2$/FiO$_2$ data (see statistics section below).

The following 25 candidate predictor variables, collected in the time period before intubation, were chosen to include in model development. Patient characteristics included: age, gender, body mass index (BMI), prior history of diabetes mellitus, hypertension, COPD, coronary artery disease, cancer or solid organ transplant. Physical examination findings included maximum temperature, lowest mean arterial pressure and lowest Glasgow Coma score in the 48 hours prior to intubation. Laboratory variables included the highest concentration of creatinine and bilirubin, and the lowest platelet count and PaO$_2$/FiO$_2$ ratio in the 48 hours prior to intubation. Management variables comprised hospital days prior to intubation; hospital days receiving non-invasive respiratory support (high-flow nasal canula oxygen; continuous positive airway pressure or bilevel positive airway pressure) prior to intubation; hospital days receiving corticosteroids (dexamethasone, methylprednisolone or prednisone) prior to intubation; and administration of any of the following drugs: corticosteroids, therapeutic dose heparin/enoxaparin, oral Xa inhibitors, subcutaneous or intravenous insulin, norepinephrine infusion. We also included intubation during surge conditions, defined as the time period(s) during which ≥ 400 ventilators (>5.5 ventilators per 100,000 population) were in use by COVID-19 patients in the state of Arizona where most of our study hospitals were located. By this criteria, surge conditions occurred in our ICUs in the summer (6/23/2020–8/7/2020) and winter (12/3/2020–2/14/2021) [37].

Variables needed to calculate the SOFA score were also extracted from the Cerner Millen- nium® electronic medical record, using the worst values in the 48 hours prior to intubation. SOFA variables include: PaO$_2$, FiO$_2$, use of invasive or non-invasive ventilatory support, lowest
MAP, use of intravenous vaspressors, GCS, platelet count, serum creatinine and bilirubin. These variables are used to assign a score of 0–4 to each of the corresponding organ systems—higher scores indicating worse organ function. The resulting cumulative SOFA score ranging from 0–24 determines predicted mortalities of 0–95% based on previous validation studies [3–5].

Data used to calculate the APACHE IVa predicted mortality were collected by direct electronic interface between Cerner Millennium® and Philips Healthcare Analytics. These included the worst physiological values occurring during the first ICU day, chronic health conditions and admission information. Predicted hospital mortality were provided by Philips Healthcare using proprietary APACHE IVa methodology (Cerner Corp. Kansas City, MO) [7].

**Study size**

We calculated that a sample size of 2500 patients would allow analysis of 25 candidate predictor variables in our logistic regression. This was based on assumed mortality of 50%, providing 25 events for each predictor variable in both the model-development and validation cohorts.

**Statistical analysis**

All study patients underwent randomization into one of the two cohorts. Missing FiO2 values were imputed as the mean FiO2 for all study patients for whom FiO2 was known. Missing PaO2 values were imputed as the mean PaO2 of all study patients receiving the same FiO2. The 25 candidate predictor variables were entered into backwards, step-wise, multiple logistic regression (MLR) using the model-development cohort, with mortality as the dependent outcome variable. We retained all variables that remained in the model at $P \leq 0.05$.

The MLR logistic equation was then applied to calculate predicted mortality for each patient in the validation cohort and this data was used to calculate area under the receiver operator curve (AUROC), Nagelkerke’s pseudo $R^2$ and Hosmer-Lemeshow goodness-of-fit tests. AUROC of all patients for whom all three predicted mortalities (C-TIME, SOFA and APACHE IVa) were calculable were compared using the Chi-squared statistic. Calibration of each of the three models were compared using calibration belts [38]. We explored model performance in relation to the assumption that a predicted mortality of $\geq 75\%$ or $\geq 90\%$ might influence the decision whether or not to intubate. Therefore, we identified patient subgroups with $\geq 75\%$ and $\geq 90\%$ predicted mortality for each of the three models, and enumerated the observed mortality for each subgroup. This allowed calculation of the sensitivity of each model for mortality (the observed mortality in each subgroup divided by overall mortality) at the two cutoffs. The Wilson method was used to calculate 95% confidence intervals for single proportions. We used STATA® Version 17 (Statacorp, College Station, TX) for all statistical analyses.

**Sensitivity analysis**

We calculated AUROCs for C-TIME and SOFA using only validation cohort patients for whom FiO2 and PaO2 were known (i.e. excluding patients with imputed values). These were compared to the AUROCs of our primary analysis by using $z$-tests on equality of proportions to test whether data imputation affected AUROC. Recalculation of APACHE IVa AUROC was not necessary because it did not incorporate imputed data.

**Results**

Between 6/1/2020 and 3/23/2021, 18,431 patients with COVID-19 were admitted to study hospitals. Of these, 4,695 were admitted to the ICU and 2,440 were intubated $\geq 4$ hours after admission. Characteristics of these 2,440 study patients are presented in the Table 1. The
Table 1. Clinical characteristics of 2440 study patients.

|                          | Model Development Cohort (n = 1,221) | Validation Cohort (n = 1,219) |
|--------------------------|-------------------------------------|--------------------------------|
| Age in years, median (IQR) | 66 (57–74)                          | 66 (56–75)                     |
| Age in years, no. (%)     |                                     |                                |
| 18–44                    | 122 (10.0%)                         | 123 (10.1%)                    |
| 45–64                    | 429 (35.1%)                         | 436 (35.8%)                    |
| 65–74                    | 395 (32.3%)                         | 347 (28.5%)                    |
| 75–84                    | 226 (18.5%)                         | 273 (22.4%)                    |
| >85                      | 49 (4.0%)                           | 40 (3.3%)                      |
| Male, no. (%)            | 740 (60.7%)                         | 762 (62.4%)                    |
| Race/ethnicity, no. (%)  |                                     |                                |
| Non-Hispanic white       | 542 (44.4%)                         | 549 (45.0%)                    |
| Hispanic                 | 481 (39.4%)                         | 462 (37.9%)                    |
| Native American          | 88 (7.2%)                           | 94 (7.7%)                      |
| African American         | 45 (3.7%)                           | 63 (5.2%)                      |
| Asian/Pacific Islander   | 22 (1.8%)                           | 18 (1.5%)                      |
| Other/Multiple Race/Unknown | 43 (3.5%)                     | 33 (2.7%)                      |
| Body Mass Index, median (IQR) | 31.3 (27.2–37.1)             | 31.8 (27.4–38.0)               |
| Admitted during surge, no. (%) | 897(73.5%)                  | 893(73.3%)                     |
| Medications, no. (%)     |                                     |                                |
| Steroids                | 1068 (87.5%)                        | 1,046 (85.8%)                  |
| Insulin                 | 655 (53.6%)                         | 680 (55.8%)                    |
| Therapeutic heparin/enoxaparin | 105 (8.6%)                 | 96 (7.9%)                      |
| Oral Xa inhibitors       | 77 (6.3%)                           | 83 (6.8%)                      |
| Norepinephrine          | 249 (20.4%)                         | 233 (19.1%)                    |
| Comorbidities, no. (%)  |                                     |                                |
| Diabetes                | 726 (59.5%)                         | 730 (60.1%)                    |
| Hypertension            | 929 (76.1%)                         | 922 (75.6%)                    |
| Coronary Artery Disease | 343 (28.1%)                         | 353 (29.0%)                    |
| COPD                    | 187 (15.3%)                         | 180 (14.8%)                    |
| Cancer                  | 117 (9.6%)                          | 126 (10.3%)                    |
| Solid organ transplant  | 17 (1.4%)                           | 17 (1.4%)                      |
| Physical examination, mean (SD) |        |                                |
| Minimum mean arterial pressure (mmHg) | 70.7 (61.7–80.3)   | 71.0 (62.3–80.0)               |
| Maximum temp (°C.)      | 99.0 (98.4–100.0)                   | 99.0 (98.4–99.9)               |
| Minimum Glasgow Coma Scale score, median (IQR) | 15 (14–15) | 15 (14–15) |
| Labs, median median (IQR) |                                      |                                |
| C-reactive protein, mg/L | 120.5 (62.4–194.8)                 | 126.6 (71.6–209.4)             |
| Creatinine**, mg/dL     | 0.93 (0.7–1.4)                      | 0.97 (0.7–1.5)                 |
| Bilirubin**, mg/dL      | 0.6 (0.4–0.8)                       | 0.5 (0.4–0.8)                  |
| PaO2/FiO2 ratio**       | 73.7 (58.0–79.0)                    | 73.7 (57.0–80.6)               |
| Platelets**, K/mm³      | 229 (163–303)                       | 223 (160–300)                  |
| Pre-intubation hospital course, median (IQR) |             |                                |
| Hours from admission to intubation | 91.8 (31.4–213.1)   | 86.5 (31.8–190.3)              |
| Days on non-invasive respiratory support before intubation | 3.0 (1.0–7.0) | 3.0 (1.0–6.0) |
| Days receiving steroids before intubation | 4.0 (1.0–8.0) | 3.0 (1.0–8.0) |
| Outcomes, no. (%)       |                                     |                                |
| In-hospital death        | 771(63.2%)                          | 789 (64.6%)                    |

(Continued)
The median age was 66 years, 61.6 percent were men, and 50.5 percent were Hispanic, Native American or African American. Eighty-six percent of patients received corticosteroids. Eleven variables were significant in the final MLR model (see Table 2). The validation cohort comprised 1,219 patients of whom 1,179 had complete data for analysis by MLR. Observed mortality in the validation cohort was 65.1%.

C-TIME AUROC was 0.75 (95%CI 0.72–0.79), Nagelkerke’s pseudo $R^2 = 0.25$, and the Hosmer-Lemeshow Chi$^2$ showed acceptable goodness-of-fit with $P = 0.29$. (Note: this $P$ value $>0.05$ shows that there is no significant difference between predicted and observed mortalities in subgroups of cohort patients, i.e., good calibration).

Two-hundred seventeen of 1179 validation cohort patients did not meet criteria for APACHE IVa calculations, and the remaining 962 patients were included in our comparison between the three models. The median (Inter-quartile range) of predicted mortality from C-TIME, SOFA and APACHE were 0.71 (0.54–0.83), 0.18 (0.07–0.26) and 0.20 (0.09–0.38) respectively. C-TIME had the highest AUROC of 0.75 (95%CI: 0.72–0.79), vs 0.67 (0.64–0.71) and 0.59 (0.55–0.62) for APACHE and SOFA, respectively (Chi$^2 P < 0.0001$) (see Fig 1). C-TIME was well calibrated (see Fig 2), with $P = 0.215$ [C-TIME predicted mortalities were not significantly different from observed mortalities]. APACHE and SOFA had poor overall calibration (see Figs 3 and 4), deviating significantly from observed mortality ($P<0.001$ for each). Calibration belt plots showed APACHE and SOFA were only acceptably calibrated when predicted mortality was $\geq 84%$ and $>73%$ respectively, and post-hoc analysis revealed

**Table 1.** (Continued)

|                                | Model Development Cohort (n = 1,221) | Validation Cohort (n = 1,219) |
|--------------------------------|-------------------------------------|-------------------------------|
| Terminal extubation and discharge to hospice | 42 (3.6%)                           | 5 (0.4%)                      |
| Combined death/discharge to hospice    | 813 (66.6%)                         | 794 (65.1%)                   |

*Race/ethnicity was as reported by the patient at time of admission.
**Variables incorporated into SOFA score.

https://doi.org/10.1371/journal.pone.0270193.t001

**Table 2.** Multiple logistic regression model with significant predictor variables for the outcome mortality in the model-development cohort.

| Significant predictor variables in the C-TIME MLR model: | Odds ratio$^*$ (95% CI) | $P$ value |
|--------------------------------------------------------|------------------------|----------|
| Age (years)                                            | 1.71 (1.47–1.98)       | $<0.001$ |
| Male Gender                                            | 1.41 (1.06–1.89)       | 0.019    |
| COPD                                                    | 1.63 (1.07–2.49)       | 0.024    |
| Minimum mean arterial pressure (mmHg)                  | 0.81 (0.70–0.93)       | 0.004    |
| Minimum Glasgow Coma Scale score                       | 0.82 (0.70–0.95)       | 0.008    |
| PaO$_2$/FiO$_2$ (mmHg)                                 | 0.73 (0.62–0.86)       | $<0.001$ |
| Maximum creatinine (mg/dl)                             | 1.17 (1.00–1.36)       | 0.050    |
| Maximum bilirubin (mg/dl)                              | 1.55 (1.13–2.13)       | 0.006    |
| Days receiving non-invasive respiratory support        | 1.52 (1.08–2.13)       | 0.017    |
| Days receiving corticosteroids                          | 1.43 (1.05–1.94)       | 0.024    |
| Received oral Xa inhibitors                            | 2.37 (1.16–4.85)       | 0.018    |

*Odds ratios are associated with a one standard deviation (SD) increment for continuous variables. Values used for SD: age: 13.7 years, MAP: 13.7 mmHg, PaO$_2$/FiO$_2$: 78.3 mmHg, creatinine: 1.9 mg/dl, bilirubin: 2.0 mg/dl, days receiving corticosteroids: 5 days; minimum Glasgow Coma Scale score: 3; days receiving non-invasive respiratory support before intubation: 5 days.

https://doi.org/10.1371/journal.pone.0270193.t002
that mortality in that range was uncommonly predicted by either method. For instance, we noted 84% of patients had SOFA scores \( \leq 9 \) corresponding with <26% mortality.

C-TIME classified 486 patients as having \( \geq 75\% \) mortality, of whom 399 died, yielding sensitivity of 50% (95%CI: 47–54%) at that cutoff. In comparison, APACHE and SOFA classified 46 and 120 patients as having \( \geq 75\% \) mortality yielding sensitivities of 5%, (95%CI:4–7%) and 12% (95%CI: 9–14%) respectively. C-TIME classified 141 patients as having \( \geq 90\% \) mortality, of whom 128 died, yielding sensitivity of 16% (95%CI: 14–19%) at that cutoff. In comparison, APACHE and SOFA classified 15 and 0 patients as having \( \geq 90\% \) mortality, yielding sensitivities of 2% (95%CI:1–3%) and zero respectively.

**Sensitivity analysis in relationship to imputed data**

Eighty percent of study patients for whom FiO\(_2\) was recorded had an FiO\(_2\) of 100%. FiO\(_2\) was imputed to be 96% in 202/2440 patients (8.3%) with missing data. PaO\(_2\) was imputed in 647/2440 patients (26.5%). Sensitivity analysis showed that C-TIME and SOFA AUROCs in the subset of 896 validation patients without imputed PaO\(_2\) were 0.75 (CI 0.71–0.79) and 0.58 (CI 0.54–0.62) respectively–identical to AUROCs calculated for the full validation cohort.
Discussion

The C-TIME mortality prediction model, based on eleven easily obtained clinical and laboratory variables, has better discriminant accuracy than APACHE IVa with 145 variables [7]. Furthermore, the C-TIME model has acceptable calibration and sensitivity in patients with high predicted mortality, in whom C-TIME may be helpful in making end-of-life decisions. Our study hospitals range from tertiary academic centers to community and critical access facilities serving a variety of persons from urban and rural communities with a wide diversity of racial/ethnic backgrounds and socioeconomic status, enhancing the external generalizability of our findings.

Well over one hundred prognostic systems, including general ICU systems (such as SOFA and APACHE), and novel systems specifically developed for COVID-19 patients have already been published to predict clinical outcomes in patients with COVID-19 [12]. These vary by target patient population, predictor variables and outcomes of interest. To provide context for C-TIME, we reviewed comparable scoring systems that were developed and validated specifically for hospitalized COVID-19 patients and which incorporated commonly available clinical and laboratory predictor variables, and which reported AUROCs for in-hospital mortality [13–34].

Several features distinguish C-TIME from other validated COVID-19 mortality prediction systems we reviewed. 1) C-TIME is the only system that specifically evaluates patients with COVID-19 pneumonia just before they require mechanical ventilation. The discriminant accuracy of other prognostic models at this point in a patient’s clinical course are unknown, due to spectrum effect (40). 2) The C-TIME study cohort had by far the highest reported mortality (65%) of any of the previous studies, as would be expected for intubated COVID-19
patients [39]. The mortality of the study cohort has a strong influence on the operating characteristics of associated mortality prediction systems [40]—another reason why previously reported mortality prediction scores are likely not accurate if used at the time of intubation. 3) Other mortality prediction systems utilized study cohorts that included patients admitted prior to 6/2020, when preliminary results of RECOVERY were released. The inclusion of significant numbers of patients who did not receive corticosteroids could limit their generalizability in relationship to current practice patterns. Eighty-six percent of our study patients received corticosteroids before intubation. 4) C-TIME is the only model that incorporates treatment variables. Days receiving corticosteroids and days receiving non-invasive respiratory support prior to intubation were associated with mortality in our model-development and validation cohorts, and were also significantly associated with surge conditions (p = 0.0003 and 0.005, respectively). Surviving patients received a median of two days steroids and two days non-invasive respiratory support; non-survivors received a median of nine days steroids and eight days non-invasive respiratory support. A recent study showed that mortality increased significantly during the winter 2020 COVID-19 surge [41] however a meta-analysis concluded that delaying intubation does not influence mortality [42]. It is possible that the associations observed in our study might be due to prolonged efforts at non-invasive respiratory support and corticosteroid treatment of patients during surge conditions, selecting treatment non-responders for intubation.

One particular C-TIME variable deserves brief comment—the association of factor Xa inhibitors with increased mortality. Analysis of a sample of these patients showed that pre-existing atrial fibrillation was the indication for factor Xa inhibitors in 80%. It is possible that receiving
factor Xa inhibitors was a confounding variable representing pre-existing atrial fibrillation in our model.

Several other mortality prediction systems with acceptable operating characteristics are available for prognostication at the *time of admission* to the hospital, rather than at the time of intubation. The 4C score is supported by the largest study cohort and has an AUROC (0.77) similar to C-TIME [13]. We noted the highest AUROCs were reported for systems that prognosticated using variables from the time of admission in Hubei province early in the pandemic [16, 22, 26, 30, 32]. We feel these results are likely irreproducible outside the special circumstances under which they were reported. This contention is supported by a study using data from the Veterans Affairs Data Warehouse [19] that externally-validated two of these prediction scores [30, 32] and found much lower AUROCs than those originally reported: 0.68 vs. 0.91, and 0.72 vs. 0.94, respectively. This phenomenon was also demonstrated for the SOFA score, which achieved AUROCs of 0.89 (0.83–0.96) [43] and 0.99 (0.98–1.00) [44] in Hubei province early in the pandemic, versus 0.58 and 0.61 (0.53–0.70) in larger, more recent studies from the US and UK [6, 15].

The calibration belt plots in Fig 2 show that C-TIME has good fit across the entire range of mortality prediction, and that APACHE and SOFA have poor fit, underestimating mortality over much of the range. Calibration is better for APACHE and SOFA when predicted mortality is above 75%. However, APACHE and SOFA uncommonly predict mortality in this range; the upper limits of their IQR for predicted mortality are 38% and 26% respectively, despite the overall mortality of 65% in the validation cohort. This is consistent with findings of our prior study which showed that SOFA is likely to under-estimate mortality in covid patients at the time of intubation because many only have single organ system failure at that point [6]. Such a
patient, receiving 100% oxygen by bilevel positive airway pressure ventilation, with a resulting \( \text{PaO}_2 \) of 55 mmHg, would have a SOFA score of 4 indicating <10% mortality. The lack of sensitivity for APACHE and SOFA at cutoffs of 75% and 90% predicted mortality would severely limit their utility in identifying high risk patients less likely to benefit from intubation.

**Limitations of the study**

Missing data was a major complication of our retrospective cohort design that limited us from including less-frequently-ordered predictor variables such as C-reactive protein, and led us to impute missing \( \text{PaO}_2 \) and \( \text{FiO}_2 \) data. Our sensitivity analysis showed that the later did not affect our AUROC estimates. Our EMR data source limited our ability to include variables not recorded as discrete data, such as COVID-19 vaccination status and pre-existing atrial fibrillation.

The discriminant accuracy achieved by C-TIME was modest, although similar to several other COVID-19 mortality prediction systems with AUROCs ranging 0.72–0.79 [15, 18, 25, 27, 29, 45]. We believe that it is inherently difficult to predict COVID-19 mortality at the time of intubation because such patients are relatively clinical homogeneous; most have life-threatening, single organ, respiratory failure (see Table 1) [3]. Low variation in predictor variables reduces discriminant accuracy. This could explain why APACHE IVa, which achieved AUROC of 0.88 in a large general ICU population [7], only yielded an AUROC of 0.66 in our study cohort.

C-TIME (and all other COVID-19 prognostic systems) are likely to lose discriminant accuracy over time, as factors influencing survival evolve. These factors might include advances in therapy and emergence of new viral strains. The aforementioned decline in discriminant accuracy for SOFA reported in Hubei vs the US and UK shows that discriminant accuracy reported in one historical setting may not be generalizable in later settings. Thus, any prognostic scoring system for COVID-19 will likely require repeated validation over time. We have begun the process of re-validating C-TIME using data collected during the Omicron surge.

**Conclusions**

C-TIME is the only currently available mortality predictive score specifically developed and validated for COVID-19 patients who require intubation. It has acceptable discriminant accuracy and goodness-of-fit to assist informed consent for intubation and other end-of-life issues that occur specifically at this critical juncture in the patient’s care. The C-TIME predicted mortality calculator can be accessed free on-line at: https://phoenixmed.arizona.edu/ctime

**Acknowledgments**

**Guarantor statement:** Dr Raschke had full access to all of the data in the study and takes personal responsibility for the integrity of the data and the accuracy of the data analysis.

**Author Contributions**

**Conceptualization:** Robert A. Raschke, Suresh Uppalapu, Nehan Sher, Steven C. Curry.

**Data curation:** Pooja Rangan, Sumit Agarwal.

**Formal analysis:** Robert A. Raschke, Pooja Rangan, Sumit Agarwal.

**Funding acquisition:** Steven C. Curry, C. William Heise.

**Investigation:** Robert A. Raschke, Sumit Agarwal.
Methodology: Robert A. Raschke, Pooja Rangan, Sumit Agarwal, Suresh Uppalapu, Nehan Sher.

Project administration: Steven C. Curry, C. William Heise.

Resources: Pooja Rangan, Sumit Agarwal, Steven C. Curry, C. William Heise.

Software: Pooja Rangan, Sumit Agarwal, C. William Heise.

Supervision: Robert A. Raschke, Steven C. Curry, C. William Heise.

Validation: Robert A. Raschke, Pooja Rangan.

Visualization: Pooja Rangan, Sumit Agarwal, Suresh Uppalapu, Steven C. Curry.

Writing – original draft: Robert A. Raschke.

Writing – review & editing: Robert A. Raschke, Pooja Rangan, Sumit Agarwal, Suresh Uppalapu, Nehan Sher, Steven C. Curry, C. William Heise.

References

1. Truog RD, Mitchell C, Daley GQ. The toughest triage—Allocating ventilators in a pandemic. N Engl J Med. 2020; 382:1973–5. https://doi.org/10.1056/NEJMp2005689 PMID: 32202721

2. Matheny AH, Gibb TS, McGuire AL, Wolpe PR et al. Ventilator triage policies during the COVID-19 pandemic at U.S. hospitals associated with members of the Association of Bioethics Program Directors. Ann Intern Med. 2020; 173:188–194. https://doi.org/10.7326/M20-1738 PMID: 32330224

3. Vincent JL, Moreno R, Takala J, Willatts S, et al. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996; 22:707–10. https://doi.org/10.1007/BF01709751 PMID: 8844239

4. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998; 26:1793–800. https://doi.org/10.1097/00003246-199811000-00016 PMID: 9824069

5. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001 Oct 10; 286(14):1754–8. https://doi.org/10.1001/jama.286.14.1754 PMID: 11594901.

6. Raschke RA, Agarwal S, Rangan P, Heise CW, Curry SC. Discriminant accuracy of the SOFA score for determining the probable mortality of patients with COVID-19 pneumonia requiring mechanical ventilation. JAMA. 2021; 325:1469–70. https://doi.org/10.1001/jama.2021.1545 PMID: 33595630

7. Zimmerman JE1, Kramer AA, McNair DS, Malia FM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today’s critically ill patients. Crit Care Med. 2006; 34:1297–1310. https://doi.org/10.1097/01.CCM.0000215112.84523.F0 PMID: 16540951

8. Keegan MT, Gajic O, Alessa B. Comparison of APACHE III, APACHE IV, SAPS 3, and MPM0III and influence of resuscitation status on model performance. Chest. 2012; 142:851–858. https://doi.org/10.1378/chest.11-2164 PMID: 22499827

9. Vasilievskis EE, Kuzniewicz MW, Cason BA, et al. Mortality probability model III and simplified acute physiology score II: assessing their value in predicting length of stay and comparison to APACHE IV. Chest. 2009; 136:89–101. https://doi.org/10.1378/chest.08-2591 PMID: 19363210

10. Vincent JL, Moreno R. Clinical review: scoring systems in the critically ill. Crit Care. 2010; 14(2):207. https://doi.org/10.1186/cc8204 PMID: 20392287

11. Vandenbrande J, Verbrugge L, Bruckers L, Geebelen L, Geerts E, Callebaut I, et al. Validation of the Acute Physiology and Chronic Health Evaluation (APACHE) II and IV Score in COVID-19 Patients. [published online Jun 19,2021] Crit Care Res Pract. 2021:5443083. https://doi.org/10.1155/2021/5443083 PMID: 34258059

12. Wynants L, Van Calster B, Collins G S, Riley R D, Heinze G, Schuit E et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. [published online Apr 7,2020] BMJ.2020; 369:m1328. https://doi.org/10.1136/bmj.m1328 PMID: 32265220
13. Knight SR, Ho A, Pius P, Buchan I. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ 2020; 370:m3339. https://doi.org/10.1136/bmj.m3339 PMID: 32907855

14. Torres-Macho J, Ryan P, Valencia J, Pérez-Butragueño M, et al. The PANDEMYC Score. An easily applicable and interpretable model for predicting mortality associated with COVID-19. J Clin Med. 2020; 9:3066. https://doi.org/10.3390/jcm9103066 PMID: 32977606

15. Berry DA, Ip A, Lewis BE, Berry SM, et al. Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19. [published online July 30,2021] PLoS One. 2021; 16:e0255228. https://doi.org/10.1371/journal.pone.0255228 PMID: 34329317

16. Weng Z, Chen Q, Li S, Li H, Zhang Q, et al. ANDC: an early warning score to predict mortality risk for patients with Coronavirus Disease 2019. J Transl Med. 2020; 18:328. https://doi.org/10.1186/s12967-020-02505-7 PMID: 32867787

17. Ghidini M, Indini A, Rijavec E, Bareggi C, et al. The appropriateness of invasive ventilation in COVID-19 positive cancer patients: Proposal of a new prognostic score. Viruses. 2021; 13:508. https://doi.org/10.3390/v13030508 PMID: 33808623

18. Halasz G, Sperti M, Villani M, Michelucci U, et al. A machine learning approach for mortality prediction in COVID-19 pneumonia: Development and evaluation of the Piacenza Score. [published online May 31,2021] J Med Internet Res. 2021; 23:e29058. https://doi.org/10.2196/29058 PMID: 33999838

19. El-Solh AA, Lawson Y, Carter M, El-Solh DA, Mergenhagen KA. Comparison of in-hospital mortality risk prediction models from COVID-19. [published online Dec 28, 2020] PLoS One. 2020; 15:e0244629. https://doi.org/10.1371/journal.pone.0244629 PMID: 33370409

20. Berenguer J, Borobia AM, Ryan P, Rodríguez-Baño J, et al; COVID-19 @Spain and COVID@HULP Study Groups. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax. 2021; 76:920–929. https://doi.org/10.1136/thoraxjnl-2020-216001 PMID: 33632764

21. Esteban Ronda V, Ruiz Alcaraz S, Ruiz Torregrosa P, Giménez Suau M, et al. Application of validated severity scores for pneumonia caused by SARS-CoV-2. Med Clin (Engl Ed). 2021; 15:99–105.

22. Chen B, Gu HQ, Liu Y, Zhang G, et al. A model to predict the risk of mortality in severely ill COVID-19 patients. Comput Struct Biotechnol J. 2021; 19:1694–1700. https://doi.org/10.1016/j.csbj.2021.03.012 PMID: 33777331

23. Chowdhury MEH, Rahman T, Khandakar A, Al-Madeed S, et al. An early warning tool for predicting mortality risk of COVID-19 patients using machine learning. [published online Apr 21, 2021] Cognit Comput. 2021; 21:1–16. https://doi.org/10.1007/s12559-020-09812-7 PMID: 33897907

24. Yan L., Zhang HT., Goncalves J. et al. An interpretable mortality prediction model for COVID-19 patients. Nat Mach Intell. 2020; 2:283–288.

25. Altschul D.J., Unda S.R., Benton J. et al. A novel severity score to predict inpatient mortality in COVID-19 patients. [published online Oct 7,2020] Sci Rep 10, 16726. https://doi.org/10.1038/s41598-020-73962-9 PMID: 33028914

26. Yuan Y, Sun C, Tang X, Cheng C, et al. Development and validation of a prognostic risk score system for COVID-19 inpatients: A multi-center retrospective study in China. [published online Nov 28,2020] Engineering (Beijing). https://doi.org/10.1007/s12559-020-09812-7 PMID: 33028444

27. Shi Y, Pandita A, Hardesty A, McCarthy M, Aridi J, Weiss ZF, et al. Validation of pneumonia prognostic scores in a statewide cohort of hospitalised patients with COVID-19. [published online Dec 31,2020] Int J Clin Pract. 2021; 75:e13926. https://doi.org/10.1111/ijcp.13926 PMID: 33296132

28. Abdulla A, Patel A, Charani E, Denny S, Mughal N, Moore L. Prognostic modeling of COVID-19 using artificial intelligence in the United Kingdom: Model development and validation. [published online Aug 25, 2020] J Med Internet Res. 2020; 22:e20259. https://doi.org/10.2196/20259 PMID: 32735549

29. Manocha KK, Kirzner J, Ying X, Yeo I, et al. Troponin and other biomarker levels and outcomes among patients hospitalized with COVID-19: Derivation and validation of the HAZT2 COVID-19 Mortality Risk Score. [published online Oct 30, 2020] J Am Heart Assoc. 2021; 10:e018477. https://doi.org/10.1161/JAHA.120.018477 PMID: 331321304

30. Chen R, Liang W, Jiang M, Guan W, et al; Medical Treatment Expert Group for COVID-19. Risk factors of fatal outcome in hospitalized subjects with Coronavirus Disease 2019 from a nationwide analysis in China. Chest. 2021; 158:97–105.

31. Sottile PD, Albers D, DeVitt PE, et al. Real-Time Electronic Health Record Mortality Prediction During the COVID-19 Pandemic: A Prospective Cohort Study. MedRxiv. [Preprint published online Jan 15 2021] https://doi.org/10.1101/2021.01.14.21249793 PMID: 33469601
32. Shang Y, Liu T, Wei Y, Li J, Shao L, Liu M, et al. Scoring systems for predicting mortality for severe patients with COVID-19. [published online Jul 3, 2020] EClinicalMedicine. 2020; 24:100426. https://doi.org/10.1016/j.eclinm.2020.100426 PMID: 32766541

33. Yu C, Lei Q, Li W, et al. Clinical characteristics, associated factors, and predicting COVID-19 mortality risk: A retrospective study in Wuhan, China. Am J Prev Med. 2020; 59:168–175. https://doi.org/10.1016/j.amepre.2020.05.002 PMID: 32564974

34. Wang K, Zuo P, Liu Y, et al. Clinical and laboratory predictors of in-hospital mortality in patients with coronavirus disease-2019: A cohort study in Wuhan, China. Clin Infect Dis. 2020; 71:2079–2088. https://doi.org/10.1093/cid/ciaa538 PMID: 32361723

35. Horby P, Lim WS, Emberson J, Mafham M, et al for the RECOVERY Collaborative Group. Effect of dexamethasone in hospitalized patients with COVID-19—Preliminary report. [published online June 22, 2020] MedRxiv 2020.06.22.2013727. https://doi.org/10.1101/2020.06.22.20137273

36. The ARDS Definition Task Force*. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA. 2012; 307:2526–2533. https://doi.org/10.1001/jama.2012.5669 PMID: 22797452

37. Arizona Department of Health Services. COVID-19 Data Dashboard. Updated daily. [Accessed 4/1/2021] https://www.azdhs.gov/covid19/data/index.php#confirmed-by-day.

38. Nattino G, Lemeshow S, Phillips G, Finazzi S, Bertolini G. Assessing the calibration of dichotomous outcome models with the calibration belt. The Stata Journal. 2017; 17:1003–1014. https://doi.org/10.1177/1536867X1801700414

39. Lim ZJ, Subramaniam A, Ponnapa Reddy M, Blecher G, et al. Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. A Meta-analysis. Am J Respir Crit Care Med. 2021; 203:54–66. https://doi.org/10.1164/rccm.202006-2405OC PMID: 33119402

40. Usher-Smith JA, Sharp SJ, Griffin SJ. The spectrum effect in tests for risk prediction, screening, and diagnosis. BMJ 2016; 353: i3139. https://doi.org/10.1136/bmj.i3139 PMID: 27334281

41. Kaddri SS, Sun J, Lawandi A, Strich JR, et al. Association between caseload surge and COVID-19 survival in 558 U.S. hospitals, March to August 2020. Ann Intern Med. 2021; 174:1240–51. https://doi.org/10.7326/M21-1213 PMID: 33422427

42. Papoutsis E, Giannakouli V.G., Xourgia E. et al. Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: a systematic review and meta-analysis of non-randomized cohort studies. Crit Care. 2021; 25:121. https://doi.org/10.1186/s13054-021-03540-6 PMID: 33766109

43. Liu S, Yao N, Qiu Y, He C. Predictive performance of SOFA and qSOFA for in-hospital mortality in severe novel coronavirus disease. Am J Emerg Med. 2020; 38:2074–2080. https://doi.org/10.1016/j.ajem.2020.07.019 PMID: 33142178

44. Yang Z, Hu Q, Huang F, Xiong S, Sun Y. The prognostic value of the SOFA score in patients with COVID-19: A retrospective, observational study. [published online Aug 13, 2021] Medicine (Baltimore). 2021; 100(32):e26900. https://doi.org/10.1097/MD.00000000000026900 PMID: 34397917

45. Moreno-Pérez Ó, Andrés M, León-Ramírez JM, et al. The COVID-GRAM Tool for Patients Hospitalized With COVID-19 in Europe. JAMA Intern Med. 2021; 181:1000–1001. https://doi.org/10.1001/jama. internmed.2021.0491 PMID: 33818609